FibroBiologics announced the issuance of a patent from the Australian Patent Office covering the proprietary method using a particular cellular blend for the regeneration of chondrocytes or cartilage-type cells. Cartilage is a vital connective tissue that provides cushioning, support, and flexibility to the joints including the spine. Cartilage tissue, due to a lack of vascularization, has a limited capacity to heal when damaged, potentially leading to pain, inflammation, and loss of function in the affected joint. FibroBiologics’ fibroblast cell-based technology offers a potential solution to regenerate cartilage tissue and restore its function, by using a natural and biocompatible cellular blend that can adapt to the specific needs of the target tissue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBLG:
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics presents data from dermal fibroblast spheroid-based treatment
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
- FibroBiologics files patent application covering fibroblast-based technology